Health Care

Joshua Levine holds 25,000 shares of EDAP TMS SA—an indicator of insider confidence amid a rally and a potential sign of future growth for the minimally invasive ultrasound company.

Acumen Pharmaceuticals’ insider sales drop shares 10.4 % to $1.86—executives sell 50,000+ shares amid low confidence and a volatile clinical‑stage market.

Insider buying fuels optimism for Enliven Therapeutics after Phase 1b success; investors eye potential upside amid high‑growth biotech volatility.

IQVIA insider buys reveal confidence in its data‑driven growth—AI‑powered analytics, high margins, and a bullish long‑term outlook for investors.

Insightful analysis of aTyr Pharma’s insider buying shows CFO & CEO confidence amid high‑risk biotech dynamics, highlighting potential upside if clinical milestones hit.

Celcuity Inc. insider sales, pipeline prospects, and valuation gaps—discover how the biotech’s strategy could unlock value or trigger risk.

Insider buying shows Sellas Life Sciences’ confidence in its oncology pipeline—watch clinical milestones that could boost a $3.86 stock’s upside.

Equillium’s insider buys reveal execs betting on a 36‑month option plan, aligning leadership with shareholder gains while driving pipeline milestones toward market entry.

Explore how aTyr Pharma’s insider option activity signals leadership confidence amid dilution risk, and what milestones investors should watch to gauge future upside.

Edwards Lifesciences insider buy by executive Daniel Lippis signals strong confidence ahead of the JenaValve acquisition, hinting at potential upside for investors.